Bionik Laboratories Announces Key Hires to Commercialization Team

Company adds strategic human capital to enhance commercialization efforts

TORONTO and BOSTON, March 14, 2017 (GLOBE NEWSWIRE) -- Bionik Laboratories Corp. (OTCQX:BNKL) (“Bionik” or the "Company"), a global pioneering robotics company focused on providing rehabilitation and mobility solutions to individuals with neurological disorders, announced today that it has made several strategic hires in the past few months to bolster the Company’s commercialization team.

Ms. Angela Maine, P.T. will serve as Southeastern Regional Sales Manager.  Angela is a licensed Physical Therapist with more than 22 years of experience specializing in the field of neurorehabilitation, and has also completed lymphedema therapy training with certification via the Lymphology Association of North America. Angela has focused much of her clinical practice with young adults through geriatrics in a variety of clinical settings. Over the last 10 years, she has transitioned her neurorehabilitation knowledge to the sales arena.  A clinical specialist, she previously served as the Former Regional Business Development Manager with Bioness Inc. During her tenure at Bioness she topped quarterly sales multiples times and was recently recognized as BD Manager of the Year 2016. 

Mr. David R. Babitsky was appointed as Northeast Regional Sales Manager. David possesses more than 20 years of medical sales experience, primarily focused in rehabilitation devices and services. His career is distinguished with a track record of delivering sales revenue, and exceeding corporate goals.  He is the former Director of Business Development at Children’s Specialized Hospital. He also worked as a Business Development Manager at Bioness for several years during the company’s initial growth period.

Ms. Marlene Fields, O.T., will serve as Central Regional Sales Manager. Marlene is a licensed Occupational Therapist with over 25 years of experience as a clinical therapist and sales manager in pediatrics and adult neuro acute rehabilitation, home health and outpatient settings. She is the former Director of Therapy for Belle Children’s Services, where she grew outreach and outpatient programs by 35%.  She previously worked as a Business Development Manager at Bioness. 

“We are extremely pleased to welcome Angela, David and Marlene to the Bionik Laboratories team,” stated Mr. Peter Bloch, Chief Executive Officer and Chairman of the Board.  “These additions to our commercial sales and clinical team reflect Bionik’s commitment to bringing our best-in-class robotics portfolio to the underserved rehabilitation and mobility solutions market.  The hiring of such highly-skilled personnel from strong industry backgrounds reinforces my optimism in our ability to expedite our commercialization efforts.”

“This investment in human capital is a strong representation of Bionik’s commitment to increasing customer satisfaction, sales, market share and brand recognition,” said Mr. Tim McCarthy, Chief Commercialization Officer. “We are currently engaged in high-level discussions with numerous industry leaders which we believe will allow us to grow the company.  We are confident that our team’s deep industry relationships will help us to achieve our primary goal of improved patient outcomes while increasing shareholder value.”

About Bionik Laboratories

Bionik Laboratories (OTCQX:BNKL), is a global, pioneering robotics company focused on providing rehabilitation and mobility solutions to individuals with neurological disorders. The Company has a portfolio of products focused on upper and lower extremity rehabilitation for stroke and other mobility impaired patients, including three products on the market and four products in varying stages of development. The InMotion Systems -- the InMotion ARM™, InMotion Wrist™, InMotion Hand™ and InMotion AnkleBot™, are designed to provide intelligent, patient-adaptive therapy in a manner that has been clinically verified to maximize neuro-recovery. Bionik is also developing a lower-body exoskeleton, ARKE™, designed to allow paraplegics as well as other wheelchair users the ability to rehabilitate through walking. ARKE is expected to be designed to continually adapt to a patient’s ability and provide real time feedback to the physiotherapist.

For more information, please visit and connect with us on Twitter, LinkedIn and Facebook.

Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development and commercialization of human exoskeletons and other robotic rehabilitation products, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company's future financial performance and (iv) the assumptions underlying or relating to any statement described in points (i), (ii) or (iii) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain additional financing, the significant length of time and resources associated with the development of our products and related insufficient cash flows and resulting illiquidity, the Company's inability to expand the Company's business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, volatility in the price of the Company's raw materials, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. The Company does not undertake to update these forward-looking statements.


Investor Relations
Bionik Laboratories
(800) 906-6498

Primary Logo

Source: Bionik Laboratories Corp.